119 related articles for article (PubMed ID: 8195833)
41. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase.
White EL; Ross LJ; Cunningham A; Escuyer V
FEMS Microbiol Lett; 2004 Mar; 232(1):101-5. PubMed ID: 15019741
[TBL] [Abstract][Full Text] [Related]
42. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454).
Sekiguchi J; Tharavichitkul P; Miyoshi-Akiyama T; Chupia V; Fujino T; Araake M; Irie A; Morita K; Kuratsuji T; Kirikae T
Antimicrob Agents Chemother; 2005 Sep; 49(9):3948-51. PubMed ID: 16127079
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of dihydropteroate synthetase from Escherichia coli by sulfones and sulfonamides.
McCullough JL; Maren TH
Antimicrob Agents Chemother; 1973 Jun; 3(6):665-9. PubMed ID: 4597736
[TBL] [Abstract][Full Text] [Related]
44. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
Walker LL; Van Landingham RM; Shinnick TM
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
[TBL] [Abstract][Full Text] [Related]
45. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
[TBL] [Abstract][Full Text] [Related]
46. A new analogous model for the detection and evaluation of chemotherapeutic products effective in leprosy.
Freerksen E; Rosenfeld M
Arzneimittelforschung; 1972 Aug; 22(8):1235-42. PubMed ID: 4678384
[No Abstract] [Full Text] [Related]
47. Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria.
Thomson CJ
J Chemother; 1993 Dec; 5(6):458-64. PubMed ID: 8195838
[TBL] [Abstract][Full Text] [Related]
48. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Gangjee A; Vasudevan A; Queener SF
J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and tolerability of brodimoprim in respiratory tract infections.
Moretti M; Marchioni CF; Bisetti A
J Chemother; 1993 Dec; 5(6):517-20. PubMed ID: 8195848
[TBL] [Abstract][Full Text] [Related]
50. Sensitivity of mycobacteria to dapsone.
Portaels F; Van den Breen L; Pattyn SR
Arzneimittelforschung; 1982; 32(9):1124-5. PubMed ID: 6890836
[TBL] [Abstract][Full Text] [Related]
51. Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis.
Dunn WJ; Hopfinger AJ; Catana C; Duraiswami C
J Med Chem; 1996 Nov; 39(24):4825-32. PubMed ID: 8941396
[TBL] [Abstract][Full Text] [Related]
52. [Comparative characterization of the antigenic composition of M. leprae and M. lufu].
Salamatina OS; Diachina MN; Iushchenko AA; Chernousova LN; Kalinina ON; Parshin MP
Probl Tuberk; 2001; (8):49-51. PubMed ID: 11767394
[TBL] [Abstract][Full Text] [Related]
53. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea.
Lee SB; Kim SK; Kang TJ; Chae GT; Chun JH; Shin HK; Kim JP; Ko YH; Kim NH
Ann Trop Med Parasitol; 2001 Jun; 95(4):429-32. PubMed ID: 11454253
[No Abstract] [Full Text] [Related]
54. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
55. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response.
Krudsood S; Imwong M; Wilairatana P; Pukrittayakamee S; Nonprasert A; Snounou G; White NJ; Looareesuwan S
Trans R Soc Trop Med Hyg; 2005 Feb; 99(2):142-9. PubMed ID: 15607340
[TBL] [Abstract][Full Text] [Related]
56. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
[TBL] [Abstract][Full Text] [Related]
57. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
Dhople AM
Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
[TBL] [Abstract][Full Text] [Related]
58. In vitro brodimoprim activity on bacterial strains.
Benoit-Lemercier C; Bergogne-Bérézin E; Joly-Guillou ML
J Chemother; 1993 Dec; 5(6):435-43. PubMed ID: 8195835
[TBL] [Abstract][Full Text] [Related]
59. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.
Matsuoka M; Budiawan T; Aye KS; Kyaw K; Tan EV; Cruz ED; Gelber R; Saunderson P; Balagon V; Pannikar V
Lepr Rev; 2007 Dec; 78(4):343-52. PubMed ID: 18309708
[TBL] [Abstract][Full Text] [Related]
60. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
